Securitisations for Life Insurers

Similar documents
Life European Actuarial Directors Forum

Insurance-Linked Securities in the life industry

Life European Actuarial Directors Forum

The future of financial reinsurance

The development of complementary insurance capacity through Insurance Linked Securities (ILS)

Alternative Risk Markets

Session 61, Overview of Embedded Value. Moderator: Zeeshan Ramzan Ali Rehmani, FSA, MAAA. Presenter: David Lawrence White, Jr.

Dervla Tomlin FSAI. Appointed Actuary

IR day 2014 SCOR s ERM ensures that the Group s risk profile and solvency are in line with its strategic plan London, 10 September 2014

Insurance-linked securities: The new UK regime Theresa Chew and Adam Levitt

Generali Investor Day 2010

Half Year Results. 27 August 2010

Life under Solvency II Be prepared!

Financial Reinsurance Proven concepts in a changing world

Guidance on the Approval and Supervision of Special Purpose Vehicles under Solvency II

Looking beyond IFRS17

Update on Solvency Assessment and Management ( SAM ) Presenter: Andre Jansen van Vuuren

Guernsey spis - private collateralised

Quarterly results

Natural Catastrophes in the Bond Market - A Trader s View

ICS Consultation Document - Responses to Comments on Asset Concentration & Credit Risks (Sections )

AVIVA Solvency and Financial Condition Report ( SFCR )

Press release Amstelveen, March 7, 2018

Guide to Financial Reporting European Embedded Value and IFRS Results year ended 31 December 2006

Accessing diversification under Solvency II: is reinsurance the answer?

SOLVENCY AND FINANCIAL CONDITION REPORT

Swiss Re's performance. Gerhard Lohmann, CFO Reinsurance KBW European Financials Conference, 16 September 2015

Recent Innovations in Longevity Risk Management; A New Generation of Tools Emerges

Quarterly statement as at 31 March 2017

Solvency II Update. Latest developments and industry challenges (Session 10) Réjean Besner

Phoenix Group. Fixed Income investor lunch. 2 October 2017

Technical Specifications part II on the Long-Term Guarantee Assessment Final version

Solvency II. Building an internal model in the Solvency II context. Montreal September 2010

THE INSURANCE BUSINESS (SOLVENCY) RULES 2015

Investment Strategies under Solvency II

Press Conference. Annual Results Hannover, 7 March 2019

Delivering Optimised Insurance Investment Strategies

Market Consistent Embedded Value Report 2016

Operating and financial review (unaudited) 2015

Reinsurance cessions in 2012: Set to rise or fall? The impact of reinsurance on risk capital

Jeff Davies. Group Chief Financial Officer

Annual EVM Results 2015 Investor and analyst presentation Zurich, 16 March We make the world more resilient.

Capital position and risk profile

LONGEVITY SWAPS. Impact of Solvency II AN EFFECTIVE, INNOVATIVE WAY TO MANAGE THE LONGEVITY RISK. Presenter: Tom O Sullivan, F.S.A, F.C.I.A, M.A.A.A.

ASSAL. Reinsurance. Walter Bell Alabama Commissioner of Insurance NAIC President

NN Group and Delta Lloyd agree on recommended transaction. Lard Friese, CEO NN Group Hans van der Noordaa, CEO Delta Lloyd 23 December 2016

Actuarial versus Financial Engineering

IFRS 17 Insurance Contracts Standard Presentation to the EFRAG Board. Mark FitzPatrick Chief Financial Officer Brussels 14 September 2017

U.K. ILS Regulations. IRLA Breakfast Briefing, December 8, Andy Palmer Swiss Re Capital Markets

Multi-arrangement Insurance Special Purpose Vehicle (MISPV) New Risk Assumption Notification Form

Annual Results Reporting 2004 Analyst presentation. Zurich, February 17, 2005

Using Reinsurance to Optimise the Solvency Position in an Insurance Company

Technical Practices Survey 2014

Solvency and Financial Condition Report 20I6

Quarterly results

Solvency II Insights for North American Insurers. CAS Centennial Meeting Damon Paisley Bill VonSeggern November 10, 2014

1. INTRODUCTION AND PURPOSE

The Review of Solvency II. 01/02/2018 Hans De Cuyper, President of Assuralia

Allianz. European Embedded Value Report

Using Solvency II to implement IFRS 17

Life Capital. Thierry Léger, CEO Life Capital Ian Patrick, CFO Life Capital

ERM Implementation and the Own Risk and Solvency Assessment (ORSA)

Hot Topic. EIOPA publishes interim technical guidelines and launches stress testing exercise. Summary. FS Regulatory Centre of Excellence

BMO FIXED INCOME INSURANCE CONFERENCE. June 15, 2017 Marlene Van den Hoogen Treasurer and Head of Capital Planning

Helvea Swiss Equities Conference. Guido Fuerer, Group Chief Investment Officer 16 January 2014

Capital allocation at the core of our strategy David Cole Group Chief Financial Officer

As a provider of financial

Investors Day 2009 Cycle management & portfolio steering

Nomura Financial Services Conference Fitter. Stronger

AIG Life Insurance Company (Switzerland) Ltd. Financial Condition Report 2017

Special Purpose Reinsurance Vehicles

Continued solid performance

Western Captive Insurance Company DAC. Solvency and Financial Condition Report. For Financial Year Ending 31 st December 2016 (the reporting period )

IFRS 17 IFRS 4 Phase II is happening, has the wait been worth it?

Best s Insurance-Linked Securities & Structures Methodology

Munich Re Market Consistent Embedded Value Report 2012

Press Release 06 November 2013 N

21 April 2017 Kurt Svoboda, CFRO. UNIQA Insurance Group AG Economic Capital and Embedded Value 2016

Solvency and Financial Condition Report Aegon Ireland

IFRS 17 will affect how reinsurers conduct business A guide to the challenges ahead

Introduction to Solvency II SCR Standard Formula for Market Risk. Erik Thoren 11 June 2015

European Solvency II Survey 2014

ERM WHAT ARE YOUR OPTIONS WHEN YOU NEED CAPITAL

Swiss Equities Conference

Actuaries Club of the Southwest

NN Group. Second quarter 2015 results. Lard Friese CEO Delfin Rueda CFO. The Hague 5 August 2015

12 April 2018 Kurt Svoboda, CFRO. UNIQA Insurance Group AG Economic Capital and Embedded Value 2017

Solvency II Implementation

In good shape. Clement B. Booth Member of the Board of Management. Morgan Stanley European Financials conference March 27th, 2012

The directors of Talanx acknowledge their responsibility for the preparation of this disclosure document.

Appendix 1: Strategy, Targets and Remittances per segment Appendix to ING Group and NN Group Press Release of 5 June 2014

Strategic positioning in a competitive market

Additional Notes. 35 Common Shares. Common Shares. Authorized Capital

ALD Re DAC SOLVENCY AND FINANCIAL CONDITION REPORT

Liability hedging in a world without risk-free assets

BERMUDA INSURANCE (GROUP SUPERVISION) RULES 2011 BR 76 / 2011

An Introduction to Solvency II

SPECIAL PURPOSE INSURERS - GUIDANCE NOTE

EUROPEAN EMBEDDED VALUE 2005

2.1 Pursuant to article 18D of the Act, an authorised undertaking shall, except where otherwise provided for, value:

Transcription:

Securitisations for Life Insurers Overview and opportunities Wolfgang Hoffmann 22. October 2013

Agenda Introduction VIF Monetisation / Securitisation Structuring of transactions Key Impact impacts on KPIs metrics, and timeframe business, process 2

Italian Market Solvency I Ratio Situation in Italy 2010 2011 2012 P&C 288% 272% 276% Life 187% 174% 199% Total 218% 204% 222% Capital is a scare resource, particularly for Life companies ( mio) 35.000 30.000 25.000 20.000 15.000 10.000 5.000 0 Life Solvency I Margin 203% 191% 198% 187% 31765 199% 170% 174% 24435 26578 27362 22722 26825 19699 15400 15990 12041 11890 11587 13444 14668 2006 2007 2008 2009 2010 2011 2012 Available Solvency I Margin Required Solvency I Margin Solvency I Ratio 250% 200% 150% 100% 50% 0% Source: IVASS Trapped capital is an obstacle to an efficient use of capital The insurance market is interested in investigating ways to fund organic and inorganic growth Italian market Solvency II Ratio (LTGA) YE11 SCR ratio Scenario 1 CCP (100%) Scenario 3 Higher CCP (250%) Scenario 6 Extended MA Alternative All Undertakings 132% 138% 182% Life Undertakings 66% 83% 209% Source: EIOPA 3

Run-off in life business is likely to increase interest to accelerate release of funds Netherlands 3 companies in formal run-off. Several individual insurers practically in run-off due to collapse of individual market UK 8 companies in run-off, representing 75 bn reserves Mid 2000 s: start of closed book consolidators Sweden 1 company in formal run-off and 7 companies closed its individual savings books Belgium One medium sized insurer recently went into run-off but not formally Germany 11 life companies in run-off with EUR 40 bn AuM (2011), which is 5% of the German market Spain no companies in formal run-off. However some companies left with savings business only, are practically in run-off Italy no companies in formal run-off. However segregated with profit funds in run-off are common and some interest exists in securitisation opportunities for with profit funds Switzerland 3 companies in formal run-off. Several individual insurers practically in run-off due to collapse of individual market 4

Agenda Introduction VIF Monetisation / Securitisation Structuring of transactions Impact Key impacts on key metrics, and business, timeframe process 5

Introduction Securitisations in the insurance industry What are securitisations? Matrix of insurance securitisation products Securitisation is the process of converting illiquid assets into assetbacked instruments which can be sold in the debt capital markets. Any type of asset with a reasonably predictable stream of future cash flows can be securitised. Securitization in the capital markets started in the banking industry in the 1970s (e.g. Asset Backed Securities, Collateralised Debt Obligations). Securitization has since evolved and reached the insurance industry in the late 1990s. Today a wide range of insurance assets/risks have been securitized successfully in the capital markets refer to exhibition on the right. P&C Life Originator (Insurance Company) Non-CAT Mass risk protection Motor insurance securitisation Financing tools by monetising future income Value of in-force (VIF) securitisations Reserve funding securitisations (eg to comply with XXX/AXXX regulation in the US) CAT (Peak risk transfer) Extreme event protection Cat-Bonds (eg Hurricanes) Sidecars Illustration of a securitisation Risk transfer SPV (Issuer / reinsurer) Extreme risk transfer Reinsurance or counterparty contract Collateral Permitted investments Mortality and longevity bonds Structured transactions for longevity / disability / health risk transfer Securities Cash Investors

VIF Monetisation / Securitisation What are VIF monetisations and securitisations? Value-of-in-force business (VIF) VIF refers to the future profits expected to emerge from a specific life insurance portfolio Estimations and calculations of VIF can be made by performing actuarial projections of the life insurance portfolio s cash flows VIF monetisations A VIF-monetisation is a transaction that allows an insurer to exchange expected future cashflows for an upfront amount of capital. Transactions often negotiated with reinsurers and / or investment banks VIF securitisations A VIF-securitisations is a specific type of VIF monetisation where securities are created The purchasers of the security exchanges the purchase price for future cash flows expected from the underlying insurance portfolio Purpose of VIF transactions Monetise future profits embedded in a block of life business Proceeds can be used for other corporate purposes (eg funding acquisitions, new business growth, special dividends or share buyback) Potentially improving capital efficiency, transferring risk and improving RoE

VIF Monetisation / Securitisation VIF monetisations and securitisations are important capital management tools Capital management toolbox Areas of Capital Management Financial/ actuarial Business management Investment Reinsurance Capital solutions Business reorganisation Review models for prudence Product redesign/ repricing Asset portfolio redesign/ restructure Reinsurance optimisation Equity raising Discontinue/ run-off certain lines of business Review actuarial reserves/dac for prudence In-force management Cashflow/ duration matching Internal reinsurance Debt structuring Reorganisation of corporate legal structures Accounting and tax optimisation Ongoing business volume/ mix management Derivatives/static/ dynamic hedging Risk transfer/ external reinsurance Contingent capital Redomiciling/ branch structures Regulatory arbitrage Underwriting and claims management Credit Financial reinsurance Sidecars or equivalent Internal captives/ resources Inter-group arrangements Expense management and outsourcing Alternative investments Securitisation Other (nonreinsurance) internal transactions Purchase/sale of business/blocks of business Possible Capital Management Actions and a useful tool Increasing to enhance Time or protect Costs group liquidity Complexity and dividend-paying capacity

VIF Monetisation / Securitisation More recent VIF monetisation and securitisation deals In the life market, VIF-monetisation and securitisation have been structured in different ways Significant further interest in Spain/Portugal and from insurers across various markets more deals expected An overview of selected prior transactions: Insurer / bancassurer Investor Date Acquired business Notable features Payment AEGON (Portofinos) - January 2007 Non-profit, unit-linked and unitised with-profits Securitisation, no monoline guarantee Unrated private placement 92m Bank of Ireland (Avondale) - October 2007 Unit-linked life and pensions Securitisation with monoline guarantee Synthetic structure based on modeled rather than actual surplus 400m Santander Abbey Life (Deutsche Bank) July 2012 Individual life risk business, including annually renewable term business & single premium term business Private placement (reinsurance) Quota share reinsurance 100% 490m CaixaBank Berkshire Hathaway November 2012 Individual life risk business, including annually renewable term business Private placement (reinsurance) Quota share reinsurance 100% 524m BBVA SCOR March 2013 Individual life risk business, including annually renewable term business & single premium term business Private placement (reinsurance) Quota share reinsurance 90% 630m BES Vida Munich Re June 2013 individual life business Private placement (reinsurance) ~ 150m Source: Company press announcements. 9

VIF Monetisation / Securitisation Key parties involved in a VIF securitisation Sponsor Investors Ultimate risk holder Investor demand is driven by spread and diversification Investor types include reinsurers, bank conduits, money managers, specialist ILS & hedge funds Service Providers Liquidity providers, monoline insurers, swap counterparties Legal Counsel Trustees SPV Administrators Optimize capital structure Manage / transfer risk Access more efficient capital Life Securitisation Regulators Approval process for reinsurance contract Evaluation / Rating of transaction contract and capital relief Rating Agencies Analyse and rate transaction Recourse considerations Treatment of capital and leverage post-transaction Modelling Agency Provide independent view of risk and cashflows May also provide services as verification and calculation agent Structure and details of transaction have to be tailored to individual purposes

Agenda Introduction VIF Monetisation / Securitisation Structuring of transactions Key impacts metrics, business, process 11

Structuring of transactions Capital markets structure Private placement Cash Insurer ILL Investor(s) Future surplus Implemented using an Insurance-Linked Loan (ILL) or reinsurance Investors directly exposed to underlying insurance risks Pros Cons Considerations Precedents for securitising UK unit-linked, non-profit and with-profits business Quicker and cheaper to implement than a public placement Small number of investors may enable achievement of greater price efficiency and increases potential flexibility of structure Scope for more complex products to be included in defined block Monetary amount that can be raised in a private transaction likely to be less than a public capital markets issue, reflecting credit exposure and illiquidity of a private placement however with lower overheads it may be more efficient to use a series of private transactions than a single public capital markets issue May still require full rating A (securitised) value of in force asset may be a reasonable asset for a pension plan Advance rate determined through a series of stress tests on underlying portfolio cash flows Potential benefit from higher effective return on capital employed financing the VIF with securitised debt rather than shareholder equity 12

Structuring of transactions Traditional capital markets structure Public placement HoldCo Cash Surplus SPV Investors LifeCo Notes Cash raised at SPV protects HoldCo as to the emergence of surplus at the insurance subsidiary Protection through counterparty contract similar to reinsurance Pros Cons Considerations Precedents for securitising UK unit-linked, non-profit (incl annuities) and with-profits business Can be on a synthetic basis to speed up implementation and reduce administration Can combine VIFs from different legal entities in one transaction Asset diversification for investors Complexity and potential inflexibility of structures Capital raised needs to be down-streamed to be used in Group Public placements may need extra due diligence, level of disclosure, independent credit ratings, etc Counterparty could be either HoldCo or LifeCo Various structures exist e.g. ISPV or ICC / PCC structures could be considered Domicile of SPV may lead to tax advantages Could use pre-agreed surplus formula or published surplus 13

Structuring of transactions Recent pure reinsurance structures seen in Spain and Portugal Reinsurer 100% quota share reinsurance on the individual life risk portfolio Insurer Reinsurer pays a price based on the value of the defined book as an upfront reinsurance commission Insurer passes the surplus to the reinsurer on a regular basis Pros Cons Considerations Single investor Relatively simple structure Profit sharing arrangements can be used to improve LTV and ensure cedant retains skin in the game Reinsurer likely to require protection against lapse risk e.g. via contractual terms such as early termination arrangements Significant haircuts to EV seen in recent European transactions Reinsurer appetite / capacity unclear in UK market Expenses typically prescribed in the surplus formula Collateral arrangements required to mitigate counterparty risks and protect policyholders Reinsurer may retrocede some of the risks Considerable negotiation required to agree terms and special clauses 14

Structuring of transactions Even one step further: a segmented risk transfer? More flexible structures could appeal to more investors Investment Investment a% Third Party Investor A Emergence of VIF Insurance/ demographics x% Third Party Investor X Insurance/ demographics b% Third Party Investor B Policyholder behaviour Policyholder behaviour c% Third Party Investor C Current securitisation arrangements lack the ability to tailor exposure investors take exposure to all the risks for a given return Splitting the emergence of VIF by drivers could allow different investors to get tailored risk exposure and get paid accordingly 15

Agenda Introduction VIF Monetisation / Securitisation Structuring of transactions Key impacts metrics, business, process 16

Impact on key metrics and timeframe High-level consideration of impact on key metrics How can a VIF securitisation impact key risk metrics of an insurance company? Solvency I Economic view Solvency 2 Liquidity Improves Pillar 1 position by cash amount raised / initial reinsurance commission No need to set up reserves as future payments to investors contingent on surplus arising VIF already recognised under Pillar 2 Could be used to turn VIF partly into cash VIF already recognised under SII although could be employed to address non-economic aspects e.g. contract boundaries, risk margin Impact on SCR will depend on extent of risk transfer and financing under chosen structure Cash raised at life companies might be up-streamed to improve capital and liquidity position of the group IFRS Under existing IFRS, we expect a direct improvement in the life company s IFRS equity although we understand that such a benefit may not arise once IFRS 4 Phase II becomes effective EV The impact on the insurer s reported EV will depend primarily on the price paid for the portfolio relative to the EV 17

Future outlook Key business considerations How much you want to raise? Debt vs equity Speed (public vs private) Duration of funding Flexibility Complexity and costs Market conditions Future proofing (Solvency II?)

Impact on key metrics and timeframe A possible timeframe for a VIF securitisation (capital market placement)* Months 1-2 Choice in-force portfolio to be securitised Consider securitisation objectives Determination of securitisation structure Creation of information memorandum document Detailed cash flow analysis (estimates / forecasts) Preparation for rating process 3-4 Results from cash flow analysis and verification of securitisation eligibility Final structure of securitisation (possibly including liquidity provider, monoline insurer, swap counterparty and reinsurance) Pricing of issue Founding of SPV Approach of rating agencies Initiation of stock exchange approval process and draft of offering circular (in case of market issuance) 5-6 Completion of documentation and legal documents Approach of investors (marketing, publication of circular etc.) / arrange distribution by investment banks Transfer of rights / assets to the SPV Close transaction *) Excludes time for rating process and is indicative only as timeframe may vary from transaction to transaction

20